BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Science '22 in Review
Top Biopharma Trends of 2022
Top Med-tech Trends of 2022
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, November 30, 2023
See today's BioWorld
See today's BioWorld Asia
Home
» MBD and Azothbio partner for rare cancer drug using AI modeling technology
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
MBD and Azothbio partner for rare cancer drug using AI modeling technology
March 3, 2020
By
Jihyun Kim
No Comments
HONG KONG – MBD Co. Ltd. and Azothbio Inc., both based in South Korea, have entered an agreement for rare cancer drug development using an AI-powered drug discovery platform.
BioWorld
BioWorld Asia
Newco news